The Health Service Executive (HSE) has approved BIMZELEX (bimekizumab) in Ireland for adults living with moderate-to-severe ...

The HS market in the 7MM offers growth through innovative biologics and small molecules by 2034, driven by key pipeline agents like sonelokimab and povorcitnib. Opportunities include in-licensing, new ...

Obesity, diabetes, and other comorbidities increase GLP-1 agonist prescriptions in hidradenitis suppurativa. Learn more.

New research reveals that switching from originator to biosimilar adalimumab for hidradenitis suppurativa may lead to reduced ...

Patient-centered nonprofit organization HS Connect recently hosted the Empower HS: Knowledge and Advocacy Workshop, an ...

Adding intense pulsed light (IPL) and radiofrequency irradiation to standard treatment significantly enhances skin improvement in patients with hidradenitis suppurativa, making the ...

A new study published in the International Journal of Dermatology showed that the individuals with concomitant arthritis had ...

Dan Baumgardt does not work for, consult, own shares in or receive funding from any company or organization that would benefit from this article, and has disclosed no relevant affiliations beyond ...

The intervention being tested is ruxolitinib cream, which is applied topically to the affected areas. This cream is intended to reduce inflammation and alleviate symptoms associated with hidradenitis ...

Intervention/Treatment: The study focuses on the drug povorcitinib, an experimental oral medication designed to treat Hidradenitis Suppurativa. Participants will continue with the treatment regimen ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Yuflyma to treat hidradenitis suppurativa and uveitis in children. The expanded indications ...

MoonLake reports mixed results from Phase 3 hidradenitis suppurativa trials ...